(1R,5S,6S)-6-[1(R)-Hydroxyethyl]-1-methyl-2-[1-(2-thiazolin-2-yl)azetidin-3-ylsulfanyl]-1-carba-2-penem-3-carboxylic acid pivaloyloxymethyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (1R,5S,6S)-6-[1(R)-Hydroxyethyl]-1-methyl-2-[1-(2-thiazolin-2-yl)azetidin-3-ylsulfanyl]-1-carba-2-penem-3-carboxylic acid pivaloyloxymethyl ester
• 英文别名: 2,2-dimethylpropanoyloxymethyl 3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
• 化学式: C₂₂H₃₁N₃O₆S₂
• 分子量: 497.6
• InChiKey: SNUDIPVBUUXCDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  159
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USE<br/>[FR] FORMES CRISTALLINES DE TEBIPÉNÈME PIVOXIL, COMPOSITIONS LES CONTENANT, PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：SPERO THERAPEUTICS INC

  公开号：WO2018145089A1

  公开（公告）日：2018-08-09

  The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

  本文披露了新的晶体型特比邦酯哌嗪盐形式，包括晶体型特比邦酯哌嗪乙烷磺酸盐形式（A型），晶体型特比邦酯哌嗪酮戊二酸盐形式（A型），特比邦酯哌嗪马来酸盐形式（A型和B型），特比邦酯哌嗪苹果酸盐形式（A型），特比邦酯哌嗪甲磺酸盐形式（B型），特比邦酯哌嗪溴化氢盐形式（B型）和特比邦酯哌嗪乙二胺盐形式（A型）。本文还包括一种组合物，包括晶体型特比邦酯哌嗪盐和药学上可接受的载体，并进一步包括一种治疗抗生素耐药细菌感染的方法，包括向需要此类治疗的患者施用治疗有效量的晶体型特比邦酯哌嗪盐。
• Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
  申请人：SPERO THERAPEUTICS, INC.

  公开号：US10889587B2

  公开（公告）日：2021-01-12

  The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

  本公开涉及新的结晶性替比培南匹伏酯盐形式，包括结晶性替比培南匹伏酯乙烷磺酸盐形式（形式 A）、结晶性替比培南匹伏酯酮戊二酸盐形式（形式 A）替比培南匹酯马来酸盐形式（形式 A 和形式 B）、替比培南匹酯苹果酸盐形式（形式 A）、替比培南匹酯甲烷磺酸盐形式（形式 B）、替比培南匹酯氢溴酸盐形式（形式 B）和替比培南匹酯乙二酸盐形式（形式 A）。本公开还包括一种组合物，该组合物由结晶的替比培南匹伏酯盐和药学上可接受的载体组成，还包括一种治疗抗生素耐药细菌感染的方法，该方法包括向需要治疗的患者施用治疗有效量的结晶的替比培南匹伏酯盐。
• TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USE
  申请人：SPERO THERAPEUTICS, INC.

  公开号：US20200055857A1

  公开（公告）日：2020-02-20

  The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.